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Abstract  26 
Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare, 27 
aggressive tumor that primarily affects young women. SCCOHT has recently been 28 
identified as a monogenic disorder caused by germline and/or somatic SMARCA4 29 
mutations. We describe a 15-year-old Caucasian girl with a SCCOHT harboring a 30 
previously unreported somatic mutation in the SMARCA4 gene 31 
(c.1757delA;p.K586.fs) with loss of heterozygosity. No germline mutation was 32 
identified. Subsequent immunohistochemical staining confirmed loss of SMARCA4 33 
protein. These molecular findings will aid with SCCOHT diagnosis through 34 
immunohistochemical staining for SMARCA4 and in the future may have 35 
implications for the management of this disease. 36 
37 
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Background 38 
Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare ovarian 39 
tumor that primarily affects adolescent and younger women, with a mean age at 40 
presentation of 23.4 years [1]. Treatment schedules are currently based on a 41 
combination of surgery and multi-agent chemotherapy but despite this the majority of 42 
patients relapse, and long-term survival is less than 33%, even in early-stage disease 43 
[1]. A better understanding of the biology of this rare tumor could assist diagnosis, 44 
rationalise treatment strategies and improve patient outcomes.  45 
 46 
The SMARCA4 protein (also known as BRG1) is a central catalytic component of the 47 
human ATP-dependent switching and sucrose non-fermenting (SWI/SNF), a 48 
chromatin-remodeling complex critically involved in the control of gene transcription 49 
within the cell [2]. Recently, deleterious somatic and germline SMARCA4 mutations 50 
have been identified in the vast majority of patients with SCCOHT, with three 51 
independent groups demonstrating immunohistochemical loss of tumoral SMARCA4 52 
protein expression in a combined total of 64/69 (92.8%) SCCOHTs [3-5]. In contrast, 53 
SMARCA4 mutations have been identified at much lower frequencies in other solid 54 
tumors [5], including Burkitt’s lymphoma and medulloblastoma [6]. 55 
 56 
SCCOHT have been noted to share similarities with another rare malignancy, namely 57 
rhabdoid tumors. Both SCCOHT and rhabdoid tumors show similar histopathological 58 
appearances and demonstrate poor responses to conventional therapy [1,7]. Mutations 59 
in another member of the SWI/SNF complex, SMARCB1, occur in 95% of all 60 
rhabdoid tumors, resulting in loss of staining for the protein product SMARCB1 (also 61 
known as INI1). The cancer genomes of both SCCOHT and rhabdoid tumors are 62 
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otherwise relatively mutationally silent, with few other mutations identified in 63 
addition to those in the SWI/SNF complex [3]. Immunohistochemical staining in 64 
rhabdoid tumors generally appears to be mutually exclusive for these proteins, in that 65 
those not showing SMARCB1 loss demonstrate SMARCA4 loss instead, and vice 66 
versa [8,9]. This clinical, pathological and molecular evidence of commonality 67 
between SCCOHT and rhabdoid tumors (both intracranial atypical teratoid/rhabdoid 68 
tumors [10] and extracranial malignant rhabdoid tumors [7]) has led to the 69 
recommendation that SCCOHT be re-classified within the rhabdoid tumor family and 70 
renamed ‘malignant rhabdoid tumor of the ovary’ (MRTO) [3,11]. Here, we report the 71 
case of a teenage girl with a SCCOHT (MRTO) harboring novel somatic biallelic 72 
SMARCA4 mutations.  73 
74 
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Case Report 75 
A previously well 15-year-old Caucasian girl presented to her local hospital with a 76 
two-week history of nausea and vomiting, lethargy and abdominal pain. Other family 77 
members were well and there was no family history of cancer. Examination revealed a 78 
large abdominal mass arising from the pelvis, confirmed by ultrasound imaging. 79 
Initial blood investigations revealed marked hypercalcemia, with a corrected calcium 80 
level of 4.79 mmol/l (reference range 2.1-2.5 mmol/l), hypomagnesemia and 81 
hypophosphatemia. Levels for all measured tumor markers were within the 82 
institutional reference ranges; namely alpha-fetoprotein (AFP) 2 kU/l (0-10 kU/l), 83 
human chorionic gonadotrophin (HCG) <2.0 U/l (0-4 U/l), carcinoembryonic antigen 84 
(CEA) <0.5 μg/l (0-5 μg/l), cancer antigen 125 (CA-125) 24 kU/l (0-30 kU/l) and 85 
lactate dehydrogenase 287 U/l (164-290 U/l). The hypercalcemia was treated with 86 
intravenous hyperhydration and disodium pamidronate, plus magnesium and 87 
phosphate supplementation. Computed tomography (CT) scan of the abdomen (Figure 88 
1A) revealed a large 11 x 9 x 10 cm solid and cystic mass centered on the left ovary, 89 
with no evidence of metastatic disease. The patient underwent a left salpingo-90 
oopherectomy and omental biopsy. At surgery, the tumor was noted to demonstrate a 91 
capsular breach. Post-operative recovery was only complicated by symptomatic 92 
rebound hypocalcemia requiring calcium gluconate infusions. 93 
   94 
Histopathological analysis showed that the ovary was replaced by haphazardly 95 
arranged small tumor cells with small nucleoli (Figure 1B). Immunohistochemical 96 
staining for inhibin was negative (Figure 1C) and CD99 demonstrated patchy 97 
positivity (Figure 1D). SMARCB1 staining was retained (Figure 1E). The omental 98 
biopsy showed no tumor involvement. Together, the clinical, surgical and 99 
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histopathological findings confirmed an International Federation of Gynaecological 100 
Oncologists (FIGO) Stage 1c SCCOHT [12]. 101 
 102 
Chemotherapy was initially commenced with two cycles of EP (etoposide and 103 
cisplatin), taking into account recent evidence [1,13] and expert opinion. Treatment 104 
was then modified in line with a protocol developed by the German MAKEI group 105 
following their report of improved outcomes with intensified multi-agent therapy 106 
[14]. The patient therefore received one course of cisplatin, ifosfamide and 107 
doxorubicin (PIA) and two subsequent courses with the carboplatin substituted for 108 
cisplatin due to impaired renal function. This was followed by consolidation with high 109 
dose carboplatin and etoposide and peripheral blood stem cell rescue. Treatment was 110 
completed seven months following presentation. End of treatment MRI 111 
abdomen/pelvis showed no evidence of disease. The patient remains well, now nine 112 
months off-treatment, with a scheduled follow-up MRI program instigated for disease 113 
surveillance. 114 
 115 
Mutation analysis of DNA from lymphocytes of the patient, and from both her 116 
parents, revealed no germline SMARCA4 mutations. Tumor DNA was extracted and 117 
analyzed using next generation and then confirmatory conventional Sanger 118 
sequencing. A (c.1757delA; p.K586.fs) mutation was identified (Figure 1F), together 119 
with intragenic loss of heterozygosity, indicating absence of the second allele. Primers 120 
used to sequence across this SMARCA4 mutation were: 5’-121 
AGTGCGCTTCTGGATTGACT -3’ and 3’-GGAAATAGAGAGAGACACGGTCA-122 
5’. Polymerase chain reaction (PCR) thermocycler conditions were used as previously 123 
described [2]. The mutation results in a deletion of amino acid 586, between the 124 
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helicase/SANT-associated (HAS) and Brahma and Kismet (BRK) domains of the 125 
SMARCA4 protein [3]. Subsequent confirmatory immunohistochemical staining 126 
revealed complete tumoral loss of SMARCA4 protein (Figure 1G). 127 
128 
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Discussion and Conclusion 129 
We report the case of a teenage girl presenting with a SCCOHT (‘malignant rhabdoid 130 
tumor of the ovary’; MRTO), harboring a novel SMARCA4 mutation with resultant 131 
loss of tumoral SMARCA4 staining. The patient remains well over a year following 132 
initial diagnosis. However, overall outcomes for this disease are poor following 133 
conventional treatment, which involves surgery and chemotherapy [1]. As SCCOHT 134 
(MRTO) largely affects young women, late effects, including subfertility, are a 135 
concern in surviving patients. 136 
 137 
The identification of a novel somatic SMARCA4 mutation in this case contributes to 138 
the growing body of evidence that SCCOHT (MRTO) is a monogenic disorder. The 139 
implication of a single gene in SCCOHT (MRTO) will not only aid with diagnosis 140 
through immunohistochemical staining for SMARCA4 [4], but may have implications 141 
for the management of this disease. Three independent groups are currently working 142 
on targeted therapies for SCCOHT (MRTO) [15], in order to improve overall survival 143 
and reduce the current dependence on high-dose conventional cytotoxic agents in this 144 
young patient population, with their associated long-term sequelae in survivors.  145 
146 
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Figure Legend 147 
Figure 1. Imaging, histopathology and mutation findings in the SCCOHT case. 148 
A) Transverse CT image of the pelvis at the time of diagnosis, demonstrating a large 149 
mass; B) Haematoxylin and eosin (H&E) stain demonstrating haphazardly arranged 150 
SCCOHT cells; C) Negative inhibin staining of the tumor cells; D) Patchy CD99 151 
staining of the tumor cells; E) Retained nuclear SMARCB1 staining of the tumor 152 
cells; F) Electrophoretogram showing the somatic homozygous SMARCA4 mutation 153 
c.1757delA; p.K586.fs; G) Loss of nuclear SMARCA4 staining of the tumor cells. 154 
155 
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